OBJECTIVE GubenyiliuⅡ(GYⅡ),a traditional Chinese medicine(TCM)formula used in our hospital,has shown beneficial effects in cancer patients.In this study,we investigated the molecular mechanisms underlying the benefi...OBJECTIVE GubenyiliuⅡ(GYⅡ),a traditional Chinese medicine(TCM)formula used in our hospital,has shown beneficial effects in cancer patients.In this study,we investigated the molecular mechanisms underlying the beneficial effects of GYⅡon murine breast cancer models.METHODS Inhibition of tumor growth and metastasis was evaluated by assessment of tumor weight and analysis of bioluminescent signal after a homograft inoculation.Viability of cultured breast cancer cells was determined using MTT assay andreal-time cell analysis(RTCA).Cell migratory ability was evaluated by Transwell?assay and wound healing assay.Subsequently,the potential anti-tumor and anti-metastatic mechanism was investigated by Western blotting and Immunohistochemistry.RESULTS GYⅡshowed significant inhibitory effects on tumor growth and metastasis in the murine breast cancer model.And GYⅡsuppressed theproliferation of 4T1 and MCF-7 cells in a dose-dependent manner.A better inhibitory effect on 4T1 cells proliferation and migration was found in sub-fractions(SF)of GYⅡ.Moreover,heparanase expression and degree of angiogenesis were reduced in tumor tissues.Western blotting analysis showed decreased expression of heparanase and growth factors in the cells treated with GYⅡand its sub-fractions(SF2 and SF3),there by a reduction in phosphorylation of ERK and AKT.CONCLUSION GYⅡexerts anti-tumor growth and anti-metastatic effects on murine breast cancer model.Sub-fractions 2 and 3 exhibits higher potency of the anti-tumor activity that is,at least partly,associated with decreased heparanase and growth factor sexpression,which subsequently sup-pressed activation of ERK and AKT pathways.展开更多
OBJECTIVE This study aims to explore the anticancer effect of fisetin for breast cancer in vivo and in vitro.METHODS Viability of cultured breast cancer cells including 4T1,Mcf-7 and MDA-MB-231 were determined using M...OBJECTIVE This study aims to explore the anticancer effect of fisetin for breast cancer in vivo and in vitro.METHODS Viability of cultured breast cancer cells including 4T1,Mcf-7 and MDA-MB-231 were determined using MTT assay and electric cell-substrate impedance sensing(ECIS).Cell migratory ability was evaluated by wound healing assay.Cell apoptosis was quantified using the AnnexinⅤ/propidium iodide(PI)detection kit and analyzed by flow cytometry.Subsequently,the potential anti-tumor and anti-metastatic mechanism was investigated by Western blotting.Inhibition of tumor growth and metastasis was evaluated by assessment of tumor weight,volume and analysis of bioluminescent signal after a homograft inoculation.Oral,intraperitoneal were respectively administered in different media.RESULTS we found that fisetin inhibited the proliferation and induced apoptosis of breast cel lines.Our study showed that fisetin inhibited migration of breast cancer cells.Importantly,our data demonstrated theanticancer activity of fisetin by oral administration.In addition,the PI3K/AKT/m TORstatus in breast cancer cells may contribute to fisetin anticancer activity.CONCLUSION Fisetin exerts anti-tumor growth and anti-metastatic effects in breast cancer cells,that is,at least partly,associated with decreased downregulation of PI3K/AKT/m TOR expression,The absolute bioavailability of intraperitoneal administration is relatively lower than that of intragastric administration,the anticancer effect of fisetin in vivo needs more study to address the solubility issue.展开更多
Objective:To study the effect and mechanism of Huayu Wan(化瘀丸,HYW)in combination of chemotherapy of tumor treatment.Methods:HYW serum was added in Lewis cells to assess its impact on fluorescent doxorubicin delivery...Objective:To study the effect and mechanism of Huayu Wan(化瘀丸,HYW)in combination of chemotherapy of tumor treatment.Methods:HYW serum was added in Lewis cells to assess its impact on fluorescent doxorubicin delivery in vitro.Then,Lewis tumor cells was implanted in C57BL/6 mice via xenograft transplantation.Tumor growth was measured and signal intensity corresponding to blood flow was assessed by laser doppler perfusion imaging(LDPI).Finally,the effect of HYW on the effificacy of doxorubicin was studied.Results:HYW can improve the transfer of fluorescent doxorubicin into cells.The blood flow signal in the tumor tissues of the HYW group was higher than that of the control group(P<0.01).Furthermore,HYW improved drug delivery of doxorubicin to tumor tissues,and this activity was associated with HYW-induced microvascular proliferation(P<0.01).Conclusions:HYW can promote microangiogenesis and increase blood supply in tumor tissues,which in turn may increase the risk of metastasis.At the same time,HYW increases drug delivery and improves the effificacy of chemotherapy drugs through vascular proliferation.Therefore,rational judgment must be exercised when considering applying HYW to an antitumor regimen.展开更多
基金The project supported by National Natural Science Foundation of China(81202840,81373815)Specialized Research Fund for the Doctoral Program of Higher Education of China(20131107110014)+1 种基金Beijing Natural Science Foundation(7162084)Swedish Cancer Foundation(150815)
文摘OBJECTIVE GubenyiliuⅡ(GYⅡ),a traditional Chinese medicine(TCM)formula used in our hospital,has shown beneficial effects in cancer patients.In this study,we investigated the molecular mechanisms underlying the beneficial effects of GYⅡon murine breast cancer models.METHODS Inhibition of tumor growth and metastasis was evaluated by assessment of tumor weight and analysis of bioluminescent signal after a homograft inoculation.Viability of cultured breast cancer cells was determined using MTT assay andreal-time cell analysis(RTCA).Cell migratory ability was evaluated by Transwell?assay and wound healing assay.Subsequently,the potential anti-tumor and anti-metastatic mechanism was investigated by Western blotting and Immunohistochemistry.RESULTS GYⅡshowed significant inhibitory effects on tumor growth and metastasis in the murine breast cancer model.And GYⅡsuppressed theproliferation of 4T1 and MCF-7 cells in a dose-dependent manner.A better inhibitory effect on 4T1 cells proliferation and migration was found in sub-fractions(SF)of GYⅡ.Moreover,heparanase expression and degree of angiogenesis were reduced in tumor tissues.Western blotting analysis showed decreased expression of heparanase and growth factors in the cells treated with GYⅡand its sub-fractions(SF2 and SF3),there by a reduction in phosphorylation of ERK and AKT.CONCLUSION GYⅡexerts anti-tumor growth and anti-metastatic effects on murine breast cancer model.Sub-fractions 2 and 3 exhibits higher potency of the anti-tumor activity that is,at least partly,associated with decreased heparanase and growth factor sexpression,which subsequently sup-pressed activation of ERK and AKT pathways.
基金The project supported by Beijing Municipal Science and Technology Commission(D161100005116005)Beijing Municipal Education Commission(KM201510025025)+1 种基金National Natural Science Foundation of China(81173239,81373815,81202840)Specialized Research Fund for the Doctoral Program of Higher Education of China(20131107110014)
文摘OBJECTIVE This study aims to explore the anticancer effect of fisetin for breast cancer in vivo and in vitro.METHODS Viability of cultured breast cancer cells including 4T1,Mcf-7 and MDA-MB-231 were determined using MTT assay and electric cell-substrate impedance sensing(ECIS).Cell migratory ability was evaluated by wound healing assay.Cell apoptosis was quantified using the AnnexinⅤ/propidium iodide(PI)detection kit and analyzed by flow cytometry.Subsequently,the potential anti-tumor and anti-metastatic mechanism was investigated by Western blotting.Inhibition of tumor growth and metastasis was evaluated by assessment of tumor weight,volume and analysis of bioluminescent signal after a homograft inoculation.Oral,intraperitoneal were respectively administered in different media.RESULTS we found that fisetin inhibited the proliferation and induced apoptosis of breast cel lines.Our study showed that fisetin inhibited migration of breast cancer cells.Importantly,our data demonstrated theanticancer activity of fisetin by oral administration.In addition,the PI3K/AKT/m TORstatus in breast cancer cells may contribute to fisetin anticancer activity.CONCLUSION Fisetin exerts anti-tumor growth and anti-metastatic effects in breast cancer cells,that is,at least partly,associated with decreased downregulation of PI3K/AKT/m TOR expression,The absolute bioavailability of intraperitoneal administration is relatively lower than that of intragastric administration,the anticancer effect of fisetin in vivo needs more study to address the solubility issue.
基金Supported by the National Natural Science Foundation of China(Nos.81603579,81873111,81673924,81774039)。
文摘Objective:To study the effect and mechanism of Huayu Wan(化瘀丸,HYW)in combination of chemotherapy of tumor treatment.Methods:HYW serum was added in Lewis cells to assess its impact on fluorescent doxorubicin delivery in vitro.Then,Lewis tumor cells was implanted in C57BL/6 mice via xenograft transplantation.Tumor growth was measured and signal intensity corresponding to blood flow was assessed by laser doppler perfusion imaging(LDPI).Finally,the effect of HYW on the effificacy of doxorubicin was studied.Results:HYW can improve the transfer of fluorescent doxorubicin into cells.The blood flow signal in the tumor tissues of the HYW group was higher than that of the control group(P<0.01).Furthermore,HYW improved drug delivery of doxorubicin to tumor tissues,and this activity was associated with HYW-induced microvascular proliferation(P<0.01).Conclusions:HYW can promote microangiogenesis and increase blood supply in tumor tissues,which in turn may increase the risk of metastasis.At the same time,HYW increases drug delivery and improves the effificacy of chemotherapy drugs through vascular proliferation.Therefore,rational judgment must be exercised when considering applying HYW to an antitumor regimen.
